정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1402 | Terminated | Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 | SARS-CoV-2 | Drug: PLN-74809 Drug: Placebo |
Phase 2 | Pliant Therapeutics, Inc. | INDUSTRY | 6 | All | 18 Years | Valleywise Health Medical Center, Phoenix, Arizona, United States Cedars-Sinai Medical Center, Los Angeles, California, United States National Jewish Health, Denver, Colorado, United States Advent Health, Orlando, Florida, United States Augusta University Medical Center, Augusta, Georgia, United States Atlantic Health System, Summit, New Jersey, United States |
| 1401 | Recruiting | Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients | COVID-19 | Drug: Melatonin Drug: The usual treatment |
Not Applicable | Mohammad Sadegh Bagheri Baghdasht | OTHER | 55 | All | 16 Years ~ 100 Years | Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of |
| 1400 | Recruiting | Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 | COVID-19 | Biological: exchange blood transfusion from normal donor Biological: plasma from convalescent patients with COVID-19 Drug: Methylene Blue 5 MG/ML |
Phase 2 | Ain Shams University | OTHER | 15 | All | 18 Years ~ 65 Years | Ain Shams University, Cairo, Egypt |
| 1399 | Recruiting | Exercise and COVID-19 Viral T-cell Immunity | Influenza | Biological: COVID-19 Vaccine | Not Applicable | University of Arizona | OTHER | 30 | All | 18 Years ~ 44 Years | University of Arizona, Tucson, Arizona, United States |
| 1398 | Not yet recruiting | ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome | Dyspnea | Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Other: Saline |
Phase 2 | Direct Biologics, LLC | INDUSTRY | 60 | All | 18 Years ~ 85 Years | |
| 1397 | Not yet recruiting | Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients | Surface-Active Agents | Drug: exogenous surfactant | Not Applicable | Shahid Beheshti University of Medical Sciences | OTHER | 60 | All | 18 Years ~ 80 Years | |
| 1396 | Recruiting | Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff | 2019 Novel Coronavirus Infection | Drug: recombinant human interferon Alpha-1b Drug: thymosin alpha 1 |
Phase 3 | Shanghai Jiao Tong University School of Medicine | OTHER | 2944 | All | 18 Years ~ 65 Years | Taihe Hospital, Shiyan, Hubei, China |